MX2021003527A - Tratamiento de baja intensidad de trastornos hematologicos. - Google Patents

Tratamiento de baja intensidad de trastornos hematologicos.

Info

Publication number
MX2021003527A
MX2021003527A MX2021003527A MX2021003527A MX2021003527A MX 2021003527 A MX2021003527 A MX 2021003527A MX 2021003527 A MX2021003527 A MX 2021003527A MX 2021003527 A MX2021003527 A MX 2021003527A MX 2021003527 A MX2021003527 A MX 2021003527A
Authority
MX
Mexico
Prior art keywords
low
hematological disorders
intensity treatment
treatment
intensity
Prior art date
Application number
MX2021003527A
Other languages
English (en)
Inventor
Qi Wang
Ronald Cheung
Stefan Faderl
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of MX2021003527A publication Critical patent/MX2021003527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención se relaciona a composiciones y métodos para tratar pacientes con trastornos proliferativos hematológicos quienes no son elegibles para el tratamiento con la quimioterapia intensiva estándar, utilizando el tratamiento de baja intensidad con CPX-351, una composición liposomal de daunorubicina y citarabina.
MX2021003527A 2018-09-25 2019-09-25 Tratamiento de baja intensidad de trastornos hematologicos. MX2021003527A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736393P 2018-09-25 2018-09-25
US201862772372P 2018-11-28 2018-11-28
PCT/US2019/052952 WO2020068979A1 (en) 2018-09-25 2019-09-25 Low-intensity treatment of hematological disorders

Publications (1)

Publication Number Publication Date
MX2021003527A true MX2021003527A (es) 2021-05-27

Family

ID=69950910

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003527A MX2021003527A (es) 2018-09-25 2019-09-25 Tratamiento de baja intensidad de trastornos hematologicos.

Country Status (11)

Country Link
US (1) US20210393665A1 (es)
EP (1) EP3856198A4 (es)
JP (1) JP2022502498A (es)
KR (1) KR20210065962A (es)
CN (1) CN113164502A (es)
AU (1) AU2019350759A1 (es)
BR (1) BR112021005539A2 (es)
CA (1) CA3114002A1 (es)
IL (1) IL281729A (es)
MX (1) MX2021003527A (es)
WO (1) WO2020068979A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3005076C (en) * 2015-11-11 2024-01-02 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
WO2022233782A1 (en) 2021-05-03 2022-11-10 Lead Discovery Center Gmbh Composition comprising an inhibitor of mitochondrial transcription

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2120568T3 (pl) * 2007-02-16 2018-03-30 Celator Pharmaceuticals, Inc. Stały stosunek leków w leczeniu krwiotwórczych nowotworów i chorób proliferacyjnych
CA3005076C (en) * 2015-11-11 2024-01-02 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
US20190151365A1 (en) * 2016-07-28 2019-05-23 Novartis Ag Combination therapies of chimeric antigen receptors and pd-1 inhibitors

Also Published As

Publication number Publication date
EP3856198A1 (en) 2021-08-04
WO2020068979A1 (en) 2020-04-02
EP3856198A4 (en) 2022-06-22
KR20210065962A (ko) 2021-06-04
CA3114002A1 (en) 2020-04-02
AU2019350759A1 (en) 2021-04-22
CN113164502A (zh) 2021-07-23
BR112021005539A2 (pt) 2021-06-29
US20210393665A1 (en) 2021-12-23
IL281729A (en) 2021-05-31
JP2022502498A (ja) 2022-01-11

Similar Documents

Publication Publication Date Title
PH12019500668A1 (en) Anti-lag-3 antibodies and compositions
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2018014154A (es) Polinucleotidos moduladores.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
MX2021012205A (es) Anticuerpos de cadena pesada que se unen al psma.
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
TW201613616A (en) Methods of treating transthyretin (TTR) mediated amyloidosis
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2020006654A (es) Métodos intraductales de tratamiento de trastornos de mama.
MX2021015337A (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MX2021003527A (es) Tratamiento de baja intensidad de trastornos hematologicos.
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2017009608A (es) Compuestos anticancerigenos.
EA202090270A1 (ru) Новые замещенные производные ксантина
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres